Synthetic modified messenger RNA for therapeutic applications
Open accessAbstract
Synthetic modified messenger RNA (mRNA) has manifested great potentials for therapeutic applications such as vaccines and gene therapies, with the recent mRNA vaccines for global pandemic COVID-19 (corona virus disease 2019) attracting the tremendous attention. The chemical modifications and delivery vehicles of synthetic mRNAs are the two key factors for their in vivo therapeutic applications. Chemical modifications like nucleoside methylation endow the synthetic mRNAs with high stability and reduced stimulation of innate immunity. The development of scalable production of synthetic mRNA and efficient mRNA formulation and delivery strategies in recent years have remarkably advanced the field. It is worth noticing that we had limited knowledge on the roles of mRNA modifications in the past. However, the last decade has witnessed not only new discoveries of several naturally occurring mRNA modifications but also substantial advances in understanding their roles on regulating gene expression. It is highly necessary to reconsider the therapeutic system made by synthetic modified mRNAs and delivery vectors. In this review, we will mainly discuss the roles of various chemical modifications on synthetic mRNAs, briefly summarize the progresses of mRNA delivery strategies, and highlight some latest mRNA therapeutics applications including infectious disease vaccines, cancer immunotherapy, mRNA-based genetic reprogramming and protein replacement, mRNA-based gene editing. STATEMENT OF SIGNIFICANCE: The development of synthetic mRNA drug holds great promise but lies behind small molecule and protein drugs largely due to the challenging issues regarding its stability, immunogenicity and potency. In the last 15 years, these issues have beensubstantially addressed by synthesizing chemically modified mRNA and developing powerful delivery systems; the mRNA therapeutics has entered an exciting new era begun with the approved mRNA vaccines for the COVID-19 infection disease. Here, we provide recent progresses in understanding the biological roles of various RNA chemical modifications, in developing mRNA delivery systems, and in advancing the emerging mRNA-based therapeutic applications, with the purpose to inspire the community to spawn new ideas for curing diseases.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
mRNA therapies must be encapsulated into safe, stable, and effective delivery vehicles to preserve the cargo from degradation and prevent immunogenicity.
“mRNA therapies must be encapsulated into safe, stable, and effective delivery vehicles to preserve the cargo from degradation and prevent immunogenicity.”
From Exosome for mRNA delivery: Strategies and therapeutic applications (2024) · cites this paper as [7]
The main obstacle to the delivery of mRNA lies in its intrinsic instability and inability to penetrate the cellular lipid bilayer.
“The main obstacle to the delivery of mRNA lies in its intrinsic instability and inability to penetrate the cellular lipid bilayer.”
From Exosome for mRNA delivery: Strategies and therapeutic applications (2024) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 213 · Cited by 89
Research works printed but not linked: 1
- [161]Walsh E.E. Frenck R.W. Jr. Falsey A.R. Kitchin N. Absalon J. Gurtman A. Lockhart S. Neuzil K. Mulligan M.J. Bailey R. Swanson K.A. Li P. Koury K. Kalina W. Cooper D. Fontes-Garfias C. Shi P.-Y. Tureci O. Tompkins K.R. Lyke K.E. Raabe V. Dormitzer P.R. Jansen K.U. Sahin U. Gruber W.C. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates 2020 The New England journal of medicine PMC7583697 33053279
- Authors
- Gao, M., Zhang, Q., Feng, X.-H., & Liu, J.
- Affiliations
- Zhejiang University (CN)
- Corresponding author
- Liu, Jianzhao
- Venue
- Acta Biomaterialia
- Publisher
- Elsevier BV
- Published
- 2021-09
- Volume
- 131
- Pages
- 1-15
- ISSN
- 1742-7061 (ISSN-L)
- PMC
- PMC8198544
- OpenAlex
- W3171799566
- Cited by
- 89
- References
- 213
- Citations by year
- 2026: 13 · 2025: 24 · 2024: 24 · 2023: 14 · 2022: 12 · 2021: 2
- FWCI
- 1.36
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Acta Biomaterialia (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (21977087, 22022702, 91853110)
- Ministry of Science and Technology of the People's Republic of China
- National Key Research and Development Program of China (2017YFA0506800)
- Startup Foundation for Hundred-Talent Program of Zhejiang University
- Fundamental Research Funds for the Central Universities
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
- Keywords
- synthetic mRNA, chemically modified mRNA, mRNA vaccines, COVID-19 vaccines, mRNA delivery systems, nucleoside methylation, mRNA stability, innate immunity, mRNA therapeutics, cancer immunotherapy, genetic reprogramming, protein replacement, infectious disease vaccines
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, Humans, Immunotherapy, RNA, Messenger
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review